Harrow (NASDAQ:HROW – Get Free Report) and Lantheus (NASDAQ:LNTH – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.
Institutional & Insider Ownership
72.8% of Harrow shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Harrow and Lantheus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harrow | -13.51% | -38.00% | -3.37% |
| Lantheus | 17.69% | 28.10% | 14.35% |
Volatility and Risk
Analyst Recommendations
This is a breakdown of current recommendations for Harrow and Lantheus, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harrow | 1 | 2 | 7 | 0 | 2.60 |
| Lantheus | 0 | 10 | 4 | 0 | 2.29 |
Harrow presently has a consensus price target of $66.17, suggesting a potential upside of 116.09%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.92%. Given Harrow’s stronger consensus rating and higher probable upside, analysts plainly believe Harrow is more favorable than Lantheus.
Earnings & Valuation
This table compares Harrow and Lantheus”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harrow | $272.30 million | 4.22 | -$5.14 million | ($1.00) | -30.62 |
| Lantheus | $1.54 billion | 4.24 | $233.56 million | $4.14 | 24.20 |
Lantheus has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Summary
Lantheus beats Harrow on 9 of the 14 factors compared between the two stocks.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
About Lantheus
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
